{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-087029","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.356045+00:00","generated_at":"2026-06-08T03:53:13.986047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Unicycive reports Q3 net loss of $4.4M; FDA alignment on OLC NDA path","bullets":["Net loss $4.4M ($0.13/share) vs $5.6M ($0.37/share) in Q3 2022; R&D expenses $3.4M, down from $4.8M.","Reached agreement with FDA on data package for OLC NDA; pivotal trial of 60 patients expected by year-end, topline data mid-2024.","Cash $14.3M expected to fund into H2 2024 including pivotal trial and topline data.","Appointed Dr. Sara Kenkare-Mitra to Board of Directors; she has experience with 100+ IND filings and 11 drug approvals.","No licensing revenue in Q3 vs $1.0M in prior period due to 2022 upfront payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-087029","json":"https://secwatch.observer/filing/0001213900-23-087029.json","markdown":"https://secwatch.observer/filing/0001213900-23-087029.md","text":"https://secwatch.observer/filing/0001213900-23-087029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023087029/0001213900-23-087029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023087029/ea188373-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:53:13.986047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9814d7a27ace93efbdbd9d46983fc52080723d2","claim":"Unicycive Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $0, EPS $0.13 per share of common stock.","evidence_excerpt":"compared to five other commercially available phosphate binders. Financial Results for the Third Quarter Ended September 30, 2023 Licensing Revenues: Licensing revenues were $0 compared to $1.0 million for the same period in 2022, due to an upfront payment for a licensing agreement entered into with Lee’s Pharmaceutical (HK) Limited in July 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023087029/0001213900-23-087029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$0"},{"label":"EPS","value":"$0.13 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}